Nalfurafine hydrochloride for the treatment of pruritus

Expert Opinion on Pharmacotherapy

Volumn 13, Issue 10, 2012, Pages 1507-1513

  Inui, Shigeki ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

opioid receptor; Haemodialysis; Nalfurafine hydrochloride; Naltrexone; Skin; Uremic pruritus

Indexed keywords

NALFURAFINE; NORBINALTORPHIMINE; PLACEBO;

ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CLINICAL PRACTICE; CONSTIPATION; DRUG ACTIVITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EOSINOPHIL; HEADACHE; HUMAN; HYPERTENSION; INSOMNIA; MAXIMUM PLASMA CONCENTRATION; MOOD; NAUSEA; NEURODERMATITIS; NONHUMAN; PRURITUS; SIDE EFFECT; SKIN CARE; SKIN DISEASE; SOMNOLENCE; SUDDEN DEAFNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; UREMIC PRURITUS; VOMITING;

DERMATOLOGIC AGENTS; HUMANS; MORPHINANS; PRURITUS; RECEPTORS, OPIOID, KAPPA; SPIRO COMPOUNDS;

EID: 84863084178     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2012.693164     Document Type: Article

References (55)

1. Pisoni RL, Wikstrom B, Elder SJ, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006;21:3495-505
2. Francos GC, Kauh YC, Gittlen SD, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991;30:884-9
3. Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003;361:690-4
4. Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol 2010;5:1410-19
5. Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: A randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004;19:3137-9
6. Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992;26:91-4
7. Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: A double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996;72:617-22
8. Gilchrest BA, Rowe JW, Brown RS, et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979;91:17-21
9. Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: A crossover randomized double-blind trial. Nephron 1994;67:270-3
10. Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: A preliminary study. Acta Dermatovenerol Croat 2005;13:97-103
11. Pauli-Magnus C, Klumpp S, Alscher DM, et al. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000;20:802-3
12. Kuypers DR, Claes K, Evenepoel P, et al. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004;19:1895-901
13. Guideline Subcommittee 'Chronic Pruritus'. EDF-Guidelines for Chronic Pruritus. European Dermatology Forum, Zurich; 2011
14. Manenti L, Vaglio A. Gabapentin for uraemic pruritus. Nephrol Dial Transplant 2005;20:1278-9
15. Gaspari A. Thalidomide neurotoxicity in dermatological patients: The next 'STEP'. J Invest Dermatol 2002;119:987-8
16. Morton CA, Lafferty M, Hau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996;11:2031-6
17. Zakrzewska-Pniewska B, Jedras M. Is pruritus in chronic uremic patients related to peripheral somatic and autonomic neuropathy? Study by R-R interval variation test (RRIV) and by sympathetic skin response (SSR). Neurophysiol Clin 2001;31:181-93
18. Johansson O, Hilliges M, Stahle-Backdahl M. Intraepidermal neuron-specific enolase (NSE)-immunoreactive nerve fibres: evidence for sprouting in uremic patients on maintenance hemodialysis. Neurosci Lett 1989;99:281-6
19. Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996;348:1552-4
20. Urbonas A, Schwartz RA, Szepietowski JC. Uremic pruritus: An update. Am J Nephrol 2001;21:343-50
21. Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. Nephrol Dial Transplant 2004;19:1338-9
22. Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus: new perspectives and insights from recent trials. Nephrol Dial Transplant 2002;17:1558-63
23. Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 2009;5:157-70
24. Kimmel M, Alscher DM, Dunst R, et al. the role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006;21:749-55
25. Kumagai H, Saruta T, Matsukawa S, Utsumi J. Prospects for a novel kappa-opioid receptor agonist, TRK-820, in uremic pruritus. In: Yosipovitch G, Greaves MW, et al. editors. Itch/basic mechanisms and therapy. Marcel Dekker, New York; 2004. p. 279-86
26. Pan ZZ. Mu-opposing actions of the kappa-opioid receptor. Trends Pharmacol Sci 1998;19:94-8
27. Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, wurafine hydrochloride, on severe itch in 337 haemodialysis patients: A phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant 2010;25:1251-7
28. Japan Dialysis Medical Science Association Statistics Investigation Committee. An overview of regular dialysis treatment in Japan as of Dec. 31, 2010. Japanese Society for Dialysis Therapy, Tokyo; 2011
29. Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: Results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000;11:514-19
30. Legroux-Crespel E, Cledes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004;208:326-30
31. Phan NQ, Bernhard JD, Luger TA, Stander S. Antipruritic treatment with systemic mu-opioid receptor antagonists: A review. J Am Acad Dermatol 2010;63:680-8
32. Szmuszkovicz J, Von Voigtlander PF. Benzeneacetamide amines: Structurally novel non-m mu opioids. J Med Chem 1982;25:1125-6
33. Millan MJ. Kappa-opioid receptors and analgesia. Trends Pharmacol Sci 1990;11:70-6
34. Nagase H, Hayakawa J, Kawamura K, et al. Discovery of a structurally novel opioid kappa-agonist derived from 4,5-epoxymorphinan. Chem Pharm Bull (Tokyo) 1998;46:366-9
35. Portoghese AS, Lipkowski AW, Takemori AE. Bimorphinans as highly selective, potent kappa opioid receptor antagonists. J Med Chem 1987;30:238-9
36. Portoghese PS, Nagase H, Lipkowski AW, et al. Binaltorphimine-related bivalent ligands and their kappa opioid receptor antagonist selectivity. J Med Chem 1988;31:836-41
37. Mori T, Nomura M, Nagase H, et al. Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats. Psychopharmacology (Berl) 2002;161:17-22
38. Nagase H. Design and synthesis of delta and kappa opioid receptor agonists and their pharmacologies. Anesth 21 Century 2008;10:1941-52
39. Togashi Y, Umeuchi H, Okano K, et al. Antipruritic activity of the kappa-opioid receptor agonist, TRK-820. Eur J Pharmacol 2002;435:259-64
40. Wakasa Y, Fujiwara A, Umeuchi H, et al. Inhibitory effects of TRK-820 on systemic skin scratching induced by morphine in rhesus monkeys. Life Sci 2004;75:2947-57
41. Seki T, Awamura S, Kimura C, et al. Pharmacological properties of TRK-820 on cloned mu-, delta- and kappa-opioid receptors and nociceptin receptor. Eur J Pharmacol 1999;376:159-67
42. Nakao K, Ikeda K, Kurokawa T, et al. Effect of TRK-820, a selective kappa opioid receptor agonist, on scratching behavior in an animal model of atopic dermatitis. Nihon Shinkei Seishin Yakurigaku Zasshi 2008;28:75-83
43. Nakao K, Mochizuki H. Nalfurafine hydrochloride: A new drug for the treatment of uremic pruritus in hemodialysis patients. Drugs Today (Barc) 2009;45:323-9
44. Ndoye A, Buchli R, Greenberg B, et al. Identification and mapping of keratinocyte muscarinic acetylcholine receptor subtypes in human epidermis. J Invest Dermatol 1998;111:410-16
45. Umeuchi H, Togashi Y, Honda T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003;477:29-35
46. Nakao K, Ando A, Hirakata M, et al. the pharmacological and clinical profiles of nalfurafine hydrochloride (Remitch-capsules 2.5 microgram), a new therapeutic agent for the treatment of uremic pruritus in hemodialysis patients. Folia Pharmacol Jpn 2010;135:205-14
47. Wikstrom B, Gellert R, Ladefoged SD, et al. Kappa-opioid system in uremic pruritus: Multicenter, randomized, double-blind, placebo-controlled clinical studies. J Am Soc Nephrol 2005;16:3742-7
48. Araujo SM, de Bruin VM, Daher ED, et al. Risk factors for depressive symptoms in a large population on chronic hemodialysis. Int Urol Nephrol 2011;publiched online 22 july 201; doi 10.1007/s11255-011-0032-9
49. Inui S, Shirakawa Y, Itami S. Effect of nalfurafine hydrochloride on pruritus and anxiety level in hemodialysis patients. J Dermatol 2011;published online 5 December 2011; doi: 10.1111/j.1346-8138.2011.01442.x.
50. Bigliardi PL, Bigliardi-Qi M, Buechner S, Rufli T. Expression of mu-opiate receptor in human epidermis and keratinocytes. J Invest Dermatol 1998;111:297-301
51. Bigliardi PL, Stammer H, Jost G, et al. Treatment of pruritus with topically applied opiate receptor antagonist. J Am Acad Dermatol 2007;56:979-88
52. Stander S, Gunzer M, Metze D, et al. Localization of mu-opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept 2002;110:75-83
53. Bigliardi-Qi M, Sumanovski LT, Buchner S, et al. Mu-opiate receptor and Beta-endorphin expression in nerve endings and keratinocytes in human skin. Dermatology 2004;209:183-9
54. Tominaga M, Ogawa H, Takamori K. Possible roles of epidermal opioid systems in pruritus of atopic dermatitis. J Invest Dermatol 2007;127:2228-35
55. Kurban MS, Boueiz A, Kibbi AG. Cutaneous manifestations of chronic kidney disease. Clin Dermatol 2008;26:255-64